Genomic characteristics of driver genes in Chinese patients with non‐small cell lung cancer

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations

(2020) J. Mazieres et al.   ANNALS OF ONCOLOGY

Treatment outcome and clinical characteristics of HER2 mutated advanced non‐small cell lung cancer patients in China

(2020) Fei Xu et al.   Thoracic Cancer

Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non–small-cell Lung Cancer: Implications of FISH-positive Patterns

(2019) Sergi Clavé et al.   Clinical Lung Cancer

Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

(2019) Narjust Duma et al.   MAYO CLINIC PROCEEDINGS

Mutation Variants and Co‐Mutations as Genomic Modifiers of Response to Afatinib in HER2‐Mutant Lung Adenocarcinoma

(2019) Wenfeng Fang et al.   ONCOLOGIST

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer

(2018) Jessica J. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma—a single center retrospective study

(2018) Nadezda P. Velizheva et al.   PATHOLOGY RESEARCH AND PRACTICE

Molecular characterization of cancers with NTRK gene fusions

(2018) Zoran Gatalica et al.   MODERN PATHOLOGY

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

(2018) David M. Hyman et al.   NATURE

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

(2017) Alexander Drilon et al.   Journal of Thoracic Oncology

TargetingBRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy

(2017) Christina S. Baik et al.   ONCOLOGIST

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

(2016) Fabrice Barlesi et al.   LANCET

Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers

(2016) Aaron M. Chapman et al.   LUNG CANCER

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials

(2016) James H. Suh et al.   ONCOLOGIST

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

(2016) J. F. Gainor et al.   Cancer Discovery

Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart

(2015) William D. Travis et al.   Journal of Thoracic Oncology

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

(2014) Yuankai Shi et al.   Journal of Thoracic Oncology

Targeting MET Amplification as a New Oncogenic Driver

(2014) Hisato Kawakami et al.   Cancers

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2

(2012) H. Greulich et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA